Home > Category > Signaling Pathways > Protein Tyrosine Kinase/RTK > VEGFR > Nintedanib Ethanesulfonate Salt

Nintedanib Ethanesulfonate Salt

ChemLeader 98+%

Catalog No：CL1034A CAS No.：656247-18-6 MDLNo： Formula：C31H33N5O4.C2H6O3S MW：649.76

Collect Share

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
10 mg	In-stock	$300.00	Visible after login	- +
25 mg	In-stock	$500.00	Visible after login	- +
50 mg	In-stock	$900.00	Visible after login	- +
100 mg	In-stock	$1600.00	Visible after login	- +

Chemical safety data sheet(MSDS)

Download MSDS

Certificate Of Authenticity(CPA)

Download COA

Inquiry Add To Cart

Product Overview
Related documents
Product details
Related literature

Product Overview

Product Name	Nintedanib Ethanesulfonate Salt
CAS	656247-18-6
Formula	C31H33N5O4.C2H6O3S
MW	649.76
Appearance	Yellow solid

Product details

BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively).1 It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs; EC50s = 7-290 nM). In vivo, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).

Related literature

Sorry, there is no relevant literature

Sorry, no related items

History

CL1034A

Nintedanib Ethanesulfonate Salt

656247-18-6 98+%